Skip Ribbon Commands
Skip to main content
Menu
Clin Assoc Prof Winnie Lam Wing Chuen

Clin Assoc Prof Lam Wing Chuen Winnie

MBBS (Singapore), FRCR (UK), FAMS

Head & Senior Consultant

Singapore General Hospital

Specialty: Nuclear Medicine and Molecular Imaging

Sub-specialties: Nuclear Medicine and Molecular Imaging

Conditions Treated by this Doctor:
Bone Mineral Densitometry (BMD), General Nuclear Medicine, Liver Tumours, Neuroendocrine Tumors, Nuclear Cardiology, Nuclear Oncology, PET/CT, Prostate Cancer, Radionuclide Bone Pain Palliation, Radiosynovectomy (Radiation synovectomy / Radiosynoviorthesis), Thyroid Cancer, Thyrotoxicosis, Y90 Microspheres.

Clinical Appointments

  • Head & Senior Consultant Nuclear Medicine and Molecular Imaging Singapore General HospitalSingapore General Hospital
  • Clinical Governance Officer Nuclear Medicine Changi General HospitalChangi General Hospital

Academic Appointments

  • Clinical Associate Professor, Duke-NUS Medical School
  • Clinical Senior Lecturer, NUS Yong Loo Lin School of Medicine
  • Clinical Teacher, Lee Kong Chian School of Medicine

Profile

Winnie completed her specialist training in nuclear medicine in 2009 and has since been contributing actively to SGH in the various aspects of clinical service, education and research. 

Notably, Winnie was the inaugural Program Director of the SingHealth Nuclear Medicine Residency Programme (2012 to 2018). She was instrumental in establishing and developing the Programme, leading it to achieve the award of Best JCST Programme in SingHealth in 2018. Winnie also served as the Director of NM Ops in the Department and as a member on various committees such as the Cluster RISPACS Steering Committee and the MOH Residency Advisory Committee. 

On the professional front, she was the Vice Chair, Chapter of Nuclear Medicine, College of Radiologists, Academy of Medicine Singapore (2013 to 2021).

Education

  • Fellow of the Academy of Medicine, Singapore in Nuclear Medicine, 2010

  • Fellow of the Royal College of Radiologists (UK), 2007

  • MBBS, National University of Singapore, 2002

Professional Appointments and Committee Memberships

  • Academic Deputy Vice Chair, Clinical Service Operations, Radiological Sciences Academic Clinical Programme, SingHealth Duke-NUS Academic Medical Centre, 2023

  • Member, Residency Advisory Committee for Nuclear Medicine, Ministry of Health, 2018

  • Member, Radiological Sciences SingHealth (RSS) Executive Committee, 2023

  • Member, Radiological Sciences Academic Clinical Programme Cluster Manpower and Clinical Operations Data Committee, 2021

  • Member, Advisory Committee on Nuclear Medicine, Ministry of Health, 2015

  • Honorary Secretary, Singapore Radiological Society, 2009-2010




Awards

  • Outstanding Faculty Award, Residency in SingHealth Excels (RiSE) Award, 2013-14

  • 10-Year Long Service Award, Singapore General Hospital

  • Silver Award, SGH Team Excellence IQC Assessment by Singapore Productivity Association 2016

Research Interests

  • Nuclear medicine

  • Molecular Imaging

Publications

  • High Thyroid Stimulating Receptor Antibody Titre and Large Goitre Size at First-Time Radioactive Iodine Treatment are Associated with Treatment Failure in Graves' Disease. Tay WL, Chng CL, Tien CS, Loke KS, Lam WW, Fook-Chong SM, Tong AK. Ann Acad Med Singapore, Jun 2019; 48 (6): 181-187

  • Myoepithelial hyperplasia: A rare mimic of breast cancer on 18F-FDG PET/CT. Tang CYL, Lam WW, Tan PH, Xie W, Peh WM, Tan VK, Leong LCH. Breast J, Apr 2020; 26(4), 775-77

  • Facing a disruptive threat: how can a nuclear medicine service be prepared for the coronavirus outbreak 2020? Lam WWC, Loke KSH, Wong WY, Ng DCE. Eur J Nucl Med Mol Imaging, Jul 2020; 47 (7): 1645-1648

  • Clinical outcomes of 177lutetium-prostate-specific membrane antigen therapy in advanced prostate cancer - a prospective pilot study in an Asian population. Thang SP, Lam WWC, Tong AKT, Allen JCJ, Ler ASL, Tay YS, Somanesan S, Kanesvaran R, Wong ASC, Ng DCE. Nucl Med Commun, Jul 2020; 41 (7): 618-628

  • Divide and Conquer: Strategies to Manage a Nuclear Medicine Department During COVID-19. Tham WY, Tong AKT, Loke KSH, Chio LY, Lim GKY, Seah XY, Ng DCE, Yan SXX, Lam WW. J Nucl Med Technol, 2020; 48(2): 98-101

  • Safeguarding children from coronavirus disease 2019: Practices of nuclear medicine units in Singapore. Cheng LTJ, Peh WM, Lam WWC. Proceedings of Singapore Healthcare, 2021; 30 (1): 36-40

  • 18F-FDG PET/CT Manifestations of IgG4-related Disease. Tang CYL, Chua WM, Cheng LTJ, Fong W, Zaheer S, Lam WW. Br J Radiol, 2021; 94 (1124): 20210105

  • Prognostication of diffuse large B-cell lymphoma patients with Deauville score of 3 or 4 at end-of-treatment PET evaluation: a comparison of the Deauville 5-point scale and the ΔSUVmax method. Ng DZ, Lee CY, Lam WW, Tong AK, Tan SH, Khoo LP, Tan YH, Chiang J, Chang ES, Chan JY, Poon EY, Somasundaram N, Rashid MFH, Tao M, Lim ST, Yang VS. Leukemia & Lymphoma, 2022, 63 (1):256-259

  • Optimization of Bayesian penalized likelihood reconstruction for 68Ga-prostate-specific membrane antigen-11 PET/computed tomography. Tang CYL, Lim GKY, Chua WM, Ng CWQ, Koo SX, Goh CX, Thang SP, Zaheer S, Lam WWC, Huang HL. Nucl Med Commun, 2023, 44

  • Semi-quantitative indices of 2-[18F]FDG PET/CT in assessing cardiovascular and non-cardiovascular manifestations of IgG4-related disease and treatment response. Chen M, Tang CYL, Fong WWS, Lam WW. EJNMMI Res, 2023, 13(1): 22

  • Outcomes and prognostic predictors of Lu‐177 PSMA radioligand therapy in metastatic castration‐resistant prostate cancer (Asian Population Study). Chua WM, Lam WW-C, Tong AK-T, Sultana R, Kua SMY, Kanesvaran R, Wong ASC, Tay KJ, Cheng TJL, Ng DCE, Thang SP. Asia Pac J Clin Oncol, 2023; 1-10

  • Radiolabeled Liposomes for Nuclear Imaging Probes. Low HY, Yang C, Xia B, He T, Lam WWC, Ng DCE. Molecules, 2023, 28(9): 3798

  • 18F-FMISO PET-guided dose escalation with multifield optimization intensity-modulated proton therapy in nasopharyngeal carcinoma. Sommat K, Tong AKT, Ong ALK, Hu J, Sin SY, Lam WWC, Xie W, Khor YM, Lim C, Lim TW, Selvarajan S, Wang F, Tan TWK, Wee JTS, Soong YL, Fong KW, Hennedige, T, Thng CH. Asia Pac J Clin Oncol, 2023; https://imsva91-ctp.trendmicro.com:443/wis/clicktime/v1/query?url=https%3a%2f%2fdoi.org%2f10.1111%2fajco.13953&umid=EBC76FA7-00CD-5506-8DDF-BFDDDD534D13&auth=6e3fe59570831a389716849e93b5d483c90c3fe4-760e899c923d8da0fa31d7c3e5c50462d18e10b3

  • Head-to-head Comparison of the Diagnostic Accuracy of Prostate-specific Membrane Antigen Positron Emission Tomography and Conventional Imaging Modalities for Initial Staging of Intermediate- to High-risk Prostate Cancer: A Systematic Review and Meta-analysis. Chow KM, So WZ, Lee HJ, Lee A, Yap DWT, Takwoingi Y, Tay KJ, Tuan J, Thang SP, Lam W, Yuen J, Lawrentschuk N, Hofman MS, Murphy DG, Chen K. European Urology, 2023

Research Trials

  • 18F-FET (O-(2-[18F]fluoroethyl)-L-tyrosine) PET in differentiating tumour progression from pseudoprogression in high grade gliomas (supported by Khoo Pilot Award (Collaborative)) - as Co-Investigator

  • 68Ga-FAPI based PET/CT for imaging Systemic sclerosis-associated Interstitial Lung Disease (SSc-ILD) (supported by SGH Research Grant) - as Co-Investigator

  • Outcomes of Radioiodine Therapy for Thyroid Cancer - as PI

  • Scheme for the Discovery of Biomarkers of Toxicity and Efficacy for CAR-T Cells - as Co-Investigator

  • FDG PET/CT in IgG4-related disease - as PI

  • Clinical utility of PET imaging in prostate cancer - as PI

  • A Phase 4, randomized, open-label, multicenter efficacy and safety study of standard dose of radium-223 dichloride vs. standard doses of novel anti-hormonal therapy (NAH) in patients with bone dominant metastatic castration resistant prostate cancer (mCRPC) progressing on/after one line of NAH -as Co-Investigator

  • Outcomes of Yttrium-90 Trans-arterial Radioembolization (Y90 TARE) - as Co-Investigator

  • Outcomes of peptide receptor radionuclide therapy (PRRT) as Co-Investigator